Minerva Neurosciences | NERV - PE Price to Earnings


Minerva Neurosciences reported 14.32 in PE Price to Earnings for its fiscal quarter ending in March of 2021.





Pe Change Date
Acadia Pharmaceuticals 10.08 1.53 Mar/2026
Adma Biologics 29.73 12.48 Dec/2025
ALKERMES 39.33 19.8 Mar/2026
AstraZeneca 29.59 2.3 Mar/2026
BioCryst Pharmaceuticals 6.06 1.07K Dec/2025
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Cipla 23.56 4.18 Mar/2026
Clal Biotechnology 11.67 2.62 Dec/2022
Compugen 4.06 75.75 Dec/2025
CSL 16.16 9.59 Dec/2025
Eli Lilly 40.27 0.06 Mar/2026
Esperion Therapeutics 129.79 129 Dec/2024
GlaxoSmithKline 14.87 3.72 Mar/2026
Grifols 11.2 1.08 Dec/2025
Halozyme Therapeutics 11.35 11.8 Mar/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
J&J 24.53 0.91 Mar/2026
Merck 16.52 2.6 Mar/2026
Neurocrine Biosciences 28.09 807.38 Mar/2026
Novartis 20.17 2.32 Mar/2026
Novavax 2.01 1.07 Dec/2025
Pfizer 9.32 5.16 Mar/2026
Roche Holding 16.09 3.51 Dec/2025
Sanofi 11.84 0.14 Mar/2026
Takeda 46.52 188.53 Mar/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023